TY - JOUR
T1 - Ocular surface toxicity of depatuxizumab mafoditin (ABT-414)
T2 - case reports
AU - Rocha-de-Lossada, Carlos
AU - Linero, Carmen Alba
AU - Ortega, Álvaro Santos
AU - Calvo-de-Mora, Marina Rodríguez
AU - Rachwani, Rahul
AU - Borroni, Davide
AU - Alba, Emilio
AU - Orgaz, Manuel Benavides
AU - Romano, Vito
PY - 2021
Y1 - 2021
N2 - The purpose of this study is to report the clinical features and outcomes of ocular surface toxicity following depatuxizumab mafoditin (ABT-414) therapy for unresectable glioblastoma. Ocular signs and symptoms of three patients treated with ABT-414 during a phase III trial for glioblastoma multiforme were evaluated. Both eyes of all patients were damaged during the week after the first infusion of the ABT-414 molecule. In all patients, mild-to-moderate keratitis could be ascertained, along with decreased visual acuity and blurred vision, as well as foreign-body sensation and redness. Symptoms and visual acuity improved 4 weeks. In conclusion, ABT-414 therapy may cause transient ocular surface toxicity. The initiation of artificial tears and lubricant ointment was enough to control the ocular surface signs and symptoms. A multidisciplinary approach, complete ophthalmologic monitorization, and elaboration of protocols are required to adequately manage these patients.
AB - The purpose of this study is to report the clinical features and outcomes of ocular surface toxicity following depatuxizumab mafoditin (ABT-414) therapy for unresectable glioblastoma. Ocular signs and symptoms of three patients treated with ABT-414 during a phase III trial for glioblastoma multiforme were evaluated. Both eyes of all patients were damaged during the week after the first infusion of the ABT-414 molecule. In all patients, mild-to-moderate keratitis could be ascertained, along with decreased visual acuity and blurred vision, as well as foreign-body sensation and redness. Symptoms and visual acuity improved 4 weeks. In conclusion, ABT-414 therapy may cause transient ocular surface toxicity. The initiation of artificial tears and lubricant ointment was enough to control the ocular surface signs and symptoms. A multidisciplinary approach, complete ophthalmologic monitorization, and elaboration of protocols are required to adequately manage these patients.
UR - https://www-webofscience-com.db.rsu.lv/wos/alldb/full-record/MEDLINE:34586240
U2 - 10.5935/0004-2749.20220039
DO - 10.5935/0004-2749.20220039
M3 - Letter
C2 - 34586240
SN - 0004-2749
VL - 85
SP - 411
EP - 414
JO - Arquivos Brasileiros de Oftalmologia
JF - Arquivos Brasileiros de Oftalmologia
IS - 4
ER -